TriangleNCT03409614 · OUTCOME
Part 2: Estimated Survival Probability
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Estimated percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 12 months, 18 months, 24 months
What was measured
OS rate at a landmark (12, 18, and 24 months) was defined as the K-M estimated probability of participants who survived due to any cause at the landmark after randomization.
Analysis population: Part 2 participants only
Groups in this outcome
Part 2: Cemiplimab + Chemotherapy
Participants received cemiplimab plus platinum-based doublet chemotherapy
Part 2: Placebo + Chemotherapy
Placebo matching cemiplimab plus platinum-based doublet chemotherapy
| Group | Source count |
|---|---|
| Part 2: Cemiplimab + Chemotherapy | 312 |
| Part 2: Placebo + Chemotherapy | 154 |
Reported measurements
12 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Cemiplimab + Chemotherapy | 66.4 | Not reported | 60.8 | 71.5 | Not reported |
| Part 2: Placebo + Chemotherapy | 53.9 | Not reported | 45.4 | 61.6 | Not reported |
18 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Cemiplimab + Chemotherapy | 53.7 | Not reported | 47.8 | 59.2 | Not reported |
| Part 2: Placebo + Chemotherapy | 35.8 | Not reported | 28.0 | 43.7 | Not reported |
24 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Cemiplimab + Chemotherapy | 43.9 | Not reported | 38.2 | 49.5 | Not reported |
| Part 2: Placebo + Chemotherapy | 27.7 | Not reported | 20.5 | 35.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 60.8
- upper Limit
- 71.5
- value
- 66.4
- group Id
- OG001
- lower Limit
- 45.4
- upper Limit
- 61.6
- value
- 53.9
- title
- 12 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 47.8
- upper Limit
- 59.2
- value
- 53.7
- group Id
- OG001
- lower Limit
- 28.0
- upper Limit
- 43.7
- value
- 35.8
- title
- 18 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 38.2
- upper Limit
- 49.5
- value
- 43.9
- group Id
- OG001
- lower Limit
- 20.5
- upper Limit
- 35.3
- value
- 27.7
- title
- 24 months
- denoms
- counts
- group Id
- OG000
- value
- 312
- group Id
- OG001
- value
- 154
- units
- Participants
- description
- OS rate at a landmark (12, 18, and 24 months) was defined as the K-M estimated probability of participants who survived due to any cause at the landmark after randomization.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received cemiplimab plus platinum-based doublet chemotherapy
- id
- OG000
- title
- Part 2: Cemiplimab + Chemotherapy
- description
- Placebo matching cemiplimab plus platinum-based doublet chemotherapy
- id
- OG001
- title
- Part 2: Placebo + Chemotherapy
- param Type
- NUMBER
- population Description
- Part 2 participants only
- reporting Status
- POSTED
- time Frame
- 12 months, 18 months, 24 months
- title
- Part 2: Estimated Survival Probability
- type
- SECONDARY
- unit Of Measure
- Estimated percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice